CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Beacon Pharmaceuticals PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Beacon Pharmaceuticals PLC
9/B/2,Toyenbee Circular Road,, Motijheel
Phone: +880 257165371p:+880 257165371 DHAKA, 1223  Bangladesh Ticker: BEACONPHARBEACONPHAR

Business Summary
Beacon Pharmaceuticals PLC, formerly Beacon Pharmaceuticals Limited, is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract manufacturing and tool manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral and biotech. Its products include Favipiravir, Remdisivir INN, Meropenem, Bendamustine, Bleomycin Sulfate, Daunorubicin, Gemcitabine, Darbepoetin alfa and Filgrastim.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Nurun NaharKarim
Director of Finance and Accounting, Chief Financial Officer Giash UddinAhmed
Executive Vice President of Sales Md. AminulHoque
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 3,872 (As of 6/30/2023)
Outstanding Shares: 231,000,000 (As of 12/31/2023)
Shareholders: 8,359
Stock Exchange: DSE
Fax Number: +880 257165379


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024